FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.
What happened
FDA inspected Lexia’s drug manufacturing facility from September 23 to 29, 2025 and found significant violations of current good manufacturing practice (CGMP), the rules for drug manufacturing. FDA found inadequate finished-product release testing (only viscosity, pH, and color were tested, not active ingredient identity/strength or objectionable microorganisms), no component identity testing or supplier qualification, no stability data for the labelled expiry, no process validation, and an inadequate quality unit. Lexia said it would stop making drug products and deregistered its drug facility.
What FDA found
Lexia did not adequately test each finished batch before release for active ingredient identity and strength or for objectionable microorganisms; it tested only viscosity, pH, and color.
21 CFR 211.165(a) and 211.165(b)Lexia did not test incoming components for identity and did not establish that suppliers’ certificate-of-analysis results were reliable.
21 CFR 211.84(d)(1) and 211.84(d)(2)Lexia assigned an expiry period to its OTC topical pain relief product without stability testing to support it.
21 CFR 211.137(a)Lexia lacked process validation data showing its manufacturing process could reproducibly make uniform, quality drug product.
21 CFR 211.100(a)Lexia lacked an adequate quality unit and written quality procedures for investigations, reserve samples, complaints, recalls, batch records, cleaning, and training.
21 CFR 211.22(a) and (d); 21 CFR 211.192; 21 CFR 211.180(e); 21 CFR 211.170(b); 21 CFR 211.198(a); 21 CFR 211.150(b); 21 CFR 211.188(b); 21 CFR 211.67(b); 21 CFR 211.25(a)
What FDA wants
FDA asks Lexia to respond in writing within 15 working days with the actions it has taken to correct the violations and prevent recurrence. If Lexia resumes drug manufacturing, FDA says it must notify the office first and provide a summary of its corrective and preventive actions.
Who should pay attention
- brands that buy OTC topical drugs from contract manufacturers
- companies that rely on supplier certificates of analysis
- quality teams responsible for stability and process validation
This is a summary. Read the original letter on fda.gov.